prikaz prve stranice dokumenta Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report
  Download
PDF 277.07 KB
Scientific paper - Case study
Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report
Molecular and Clinical Oncology, 6 (2017), 6; 921-924. https://doi.org/10.3892/mco.2017.1248
Sreter, Katherina Bernadette; Barisic, Blazenka; Barisic Kutija, Marija; Kukulj, Suzana; Samarzija, Miroslav

Cite this document

Sreter, K. B., Barisic, B., Barisic Kutija, M., Kukulj, S. & Samarzija, M. (2017). Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report. Molecular and Clinical Oncology, 6. (6), 921-924. doi: 10.3892/mco.2017.1248

Sreter, Katherina Bernadette, et al. "Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report." Molecular and Clinical Oncology, vol. 6, no. 6, 2017, pp. 921-924. https://doi.org/10.3892/mco.2017.1248

Sreter, Katherina Bernadette, Blazenka Barisic, Marija Barisic Kutija, Suzana Kukulj and Miroslav Samarzija. "Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report." Molecular and Clinical Oncology 6, no. 6 (2017): 921-924. https://doi.org/10.3892/mco.2017.1248

Sreter, K. B., et al. (2017) 'Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report', Molecular and Clinical Oncology, 6(6), pp. 921-924. doi: 10.3892/mco.2017.1248

Sreter KB, Barisic B, Barisic Kutija M, Kukulj S, Samarzija M. Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report. Molecular and Clinical Oncology [Internet]. 2017 June [cited 2024 December 11];6(6):921-924. doi: 10.3892/mco.2017.1248

K. B. Sreter, B. Barisic, M. Barisic Kutija, S. Kukulj and M. Samarzija, "Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report", Molecular and Clinical Oncology, vol. 6, no. 6, pp. 921-924, June 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:114533. [Accessed: 11 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report
AuthorKatherina Bernadette Sreter
AuthorBlazenka Barisic
AuthorMarija Barisic Kutija
AuthorSuzana Kukulj
AuthorMiroslav Samarzija
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Adie's syndrome (AS) and paraneoplastic sensorimotor neuropathy with cerebellar ataxia (PSN CA) are extremely rare, rapidly progressive, autoimmune diseases associated with the development of antibodies against neuronal-specific Hu proteins that are abnormally expressed in small-cell lung cancer (SCLC). We herein present the unique case of a 55-year-old obese woman, previous heavy smoker, who, during treatment with standard cisplatin-etoposide chemotherapy for limited-stage SCLC, developed simultaneous AS and worsening symptoms consistent with PSN CA that led to significant neurological disability and severe axonal electrophysiological pattern on nerve conduction studies. Serology confirmed the presence of low-titre type 1 antineuronal nuclear antibodies (ANNA-1), previously referred to as anti-Hu antibodies. Following plasmapheresis, immunosuppressive therapy and physical rehabilitation, the neurological symptoms progressively improved. The tumour completely regressed, with no recurrence detected on subsequent radiological examinations. The aim of this case was to highlight the importance of a multidisciplinary team approach for early recognition and rapid treatment of paraneoplastic neurological syndromes (PNS) as key to achieving significant recovery and marked improvement of the neurological deficit. This report extends the literature by confirming earlier studies showing that the presence of serum ANNA-1 in SCLC, an aggressive type of pulmonary carcinoma that is challenging to treat, may portend a more favourable prognosis and response to chemotherapy. Thus, patients with SCLC and new-onset neurological symptoms should be tested for ANNA-1. The role of a multimodality approach to treating PNS is also emphasized.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMolecular and Clinical Oncology
Numberingvol. 6, no. 6, pp. 921-924
p-ISSN2049-9450
e-ISSN2049-9469
DOIhttps://doi.org/10.3892/mco.2017.1248
URN:NBNurn:nbn:hr:220:114533
Publication2017-06
Document URLhttps://www.spandidos-publications.com/10.3892/mco.2017.1248
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-10-02 09:15:58